Stockreport

VYNE Therapeutics Reports Positive Top-line Phase 1a MAD Data for VYN202, its Novel BD2-Selective BET Inhibitor [Yahoo! Finance]

VYNE Therapeutics Inc.  (VYNE) 
PDF Consistent with Phase 1a SAD results, VYN202 demonstrated a favorable safety and tolerability profile with no drug-related adverse events historically associated with e [Read more]